fingolimod hydrochloride has been researched along with Malignant Melanoma in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (91.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Carbone, ML; De Giglio, L; Failla, CM; Lacal, PM; Mazzanti, C; Messinese, S; Pagnanelli, G; Persechino, S; Pozzilli, C | 1 |
| Hoogervorst, ELJ; Killestein, J; Leurs, CE; Mostert, JP; Uitdehaag, BMJ; van den Eertwegh, AJM; van Eijk, J | 1 |
| Abe, N; Banno, Y; Kanoh, H; Seishima, M; Takahashi, T | 1 |
| Bastien, M; Cavalcanti, A; Chochon, F; Lubetzki, C; Robert, C; Routier, E; Thomas, M; Velter, C | 1 |
| Bugnon, O; Mazellier, S; Michiels, JF; Michiels, Y | 1 |
| Banno, Y; Fujine, E; Ishitsuka, A; Kanoh, H; Mizutani, Y; Seishima, M; Tawada, C | 1 |
| Chi, M; Guo, ST; Jiang, CC; Jin, L; Liu, X; Tay, KH; Tseng, HY; Verrills, NM; Zhang, XD | 1 |
| Enjoji, S; Fujiwara, N; Mizuno, T; Nakagawa, T; Ohama, T; Sato, K; Tsuji, S; Usui, T; Vitek, MP; Yabe, R | 1 |
| Haebich, G; Mughal, A; Tofazzal, N | 1 |
| Guo, M; Robinson, CL | 1 |
| Braun, R; Conzett, KB; Dummer, R; French, LE; Hofbauer, GF; Jelcic, I; Kamarachev, J; Kolm, I; Linnebank, M | 1 |
| Gerdes, LA; Havla, JB; Hohlfeld, R; Kümpfel, T; Meinl, I; Pellkofer, HL | 1 |
1 review(s) available for fingolimod hydrochloride and Malignant Melanoma
| Article | Year |
|---|---|
Multiple Sclerosis Treatment and Melanoma Development.
Topics: Antirheumatic Agents; Biomarkers; Biopsy; Disease Susceptibility; Female; Fingolimod Hydrochloride; Humans; Immunohistochemistry; Immunosuppressive Agents; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Multiple Sclerosis; Natalizumab; Skin Neoplasms; Vascular Endothelial Growth Factor A | 2020 |
11 other study(ies) available for fingolimod hydrochloride and Malignant Melanoma
| Article | Year |
|---|---|
Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS.
Topics: Adult; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Melanoma; Middle Aged; Multiple Sclerosis; Netherlands; Young Adult | 2017 |
Synergistic effects of vemurafenib and fingolimod (FTY720) in vemurafenib‑resistant melanoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Fingolimod Hydrochloride; Humans; Melanoma; Proto-Oncogene Proteins c-akt; Signal Transduction; Vemurafenib | 2018 |
Melanoma during fingolimod treatment for multiple sclerosis.
Topics: Back; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Melanoma; Middle Aged; Multiple Sclerosis; Natalizumab; Risk Factors; Skin Neoplasms | 2019 |
Detection of a new melanoma in a patient treated with fingolimod.
Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Melanoma; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nevus, Pigmented; Skin Neoplasms; Treatment Outcome; Withholding Treatment | 2019 |
FTY720 and cisplatin synergistically induce the death of cisplatin-resistant melanoma cells through the downregulation of the PI3K pathway and the decrease in epidermal growth factor receptor expression.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Fingolimod Hydrochloride; Humans; Inhibitory Concentration 50; Lysophospholipids; Melanoma; Phosphatidylinositol 3-Kinases; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Signal Transduction; Sphingosine | 2014 |
Involvement of vacuolar H(+)-ATPase in killing of human melanoma cells by the sphingosine kinase analogue FTY720.
Topics: Adenosine Triphosphate; Autophagy; Cell Death; Cell Line, Tumor; Cell Membrane; Dimethyl Sulfoxide; Fingolimod Hydrochloride; Humans; Macrolides; Melanoma; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Protein Phosphatase 2; Reactive Oxygen Species; Sphingosine; Vacuolar Proton-Translocating ATPases | 2015 |
The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dog Diseases; Dogs; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Chaperones; Melanoma; Neoplasm Proteins; Peptides; Transcription Factors | 2015 |
Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis.
Topics: Adult; Ankle; Female; Fingolimod Hydrochloride; Humans; Melanoma; Melanoma, Cutaneous Malignant; Multiple Sclerosis, Relapsing-Remitting; Skin Neoplasms | 2016 |
Fingolimod (Gilenya) and melanoma.
Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Multiple Sclerosis; Skin Neoplasms | 2016 |
Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Melanoma; Multiple Sclerosis; Propylene Glycols; Skin Neoplasms; Sphingosine | 2011 |
Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
Topics: Brain; Disability Evaluation; Disease Progression; Fingolimod Hydrochloride; Humans; Immunologic Factors; Interferon-beta; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Recurrence; Sphingosine; Treatment Outcome | 2012 |